EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

Psilocybin-gestützte Gruppentherapie und Mindfulness-Based Stress Reduction bei COVID-19-bedingter Depression und Burnout bei Frontline-Gesundheitsfachpersonen: randomisierte kontrollierte Studie

Benjamin R Lewis iD, John Hendrick, Kevin Byrne iD, Madeleine Odette iD, Chaorong Wu, Eric L Garland

PLOS Medicine · 19.09.2025 · 22 (9) · e1004519

DOI: 10.1371/journal.pmed.1004519 ↗

Auf einen Blick

Bei 25 Ärzt:innen und Pflegefachpersonen führte MBSR plus Psilocybin zu einem stärkeren Rückgang depressiver Symptome als MBSR allein. Schwerwiegende unerwünschte Ereignisse traten nicht auf.

Fragestellung

Verbessert Psilocybin plus MBSR im Vergleich zu MBSR allein depressive Symptome und Burnout bei Frontline-Gesundheitsfachpersonen mit COVID-19-bezogener Depression und Burnout?

Methode

Randomisierte kontrollierte Studie; 1:1-Zuteilung zu 8 Wochen MBSR allein oder MBSR plus gruppenbasierter psilocybin-gestützter Psychotherapie mit 25 mg Psilocybin; Erfassung bis 6 Monate.

Ergebnisse

25 Teilnehmende. QIDS-SR-16: zwischen den Gruppen Effekt = 4,6 (95 %-KI 1,51–7,70; p = 0,008) zugunsten von MBSR + PAP; Effekt nach 6 Monaten abgeschwächt. 12 studienbezogene Grad 1–2 AEs, keine schweren AEs.

Einschränkungen

Kleine Stichprobe, homogene Studienpopulation und deutliche Unterschiede in der Intensität der Interventionen schränken die Übertragbarkeit ein.

Schlussfolgerung der Autor:innen

Die Studie erreichte den primären Endpunkt: Gruppen-PAP plus MBSR war mit einer klinisch relevanten Besserung depressiver Symptome ohne schwere AEs und mit stärkerer Symptomreduktion als MBSR allein verbunden.

Kernaussagen

  • MBSR + Psilocybin besser als MBSR allein für QIDS-SR-16
  • Keine schweren unerwünschten Ereignisse
  • Sekundäre Endpunkte begünstigten die Kombinationsgruppe, aber nicht nach Korrektur

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 19.09.2025. Verfasst von Benjamin R Lewis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Mental Health Institute, University of Utah, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Mindfulness, COVID-19, Psilocybin, Burnout, Professional. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NCATS NIH HHS, NIDA NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR versus MBSR alone for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. We hypothesized that psilocybin would augment the antidepressant effects of MBSR in this population. Methods and findings We conducted a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and burnout. (ClinicalTrials.gov Identifier: NCT05557643) Participants were enrolled between January 2nd, 2023 and January 16th, 2024, and randomized in a 1:1 ratio to either an 8-week MBSR curriculum alone or an 8-week MBSR curriculum plus group psilocybin-assisted psychotherapy (PAP) with 25 mg psilocybin. Evaluation of safety and feasibility of enrollment and retention was a primary objective of the study. The primary efficacy endpoint was change in depressive symptoms, as measured by the Quick Inventory of Depressive Symptoms (QIDS-SR-16) at 2 weeks post-intervention. Symptoms of depression and burnout were assessed at baseline, and 2 weeks and 6 months post-intervention utilizing the Quick Inventory of Depressive Symptoms (QIDS-SR-16) and Maslach Burnout Inventory Human Services Survey for Medical Professionals (MBI-HSS-MP), respectively. Secondary outcome measures included the Demoralization Scale (DS-II) and the Watt’s Connectedness Scale (WCS). Adverse events (AEs) and suicidality were assessed through a 6-month follow-up. Twenty-five participants were enrolled and randomized. Safety was a study outcome and assessed by rate and severity of AEs and any incident suicidality or significant mental health symptoms. Baseline and outcome data were summarized using descriptive statistics, with continuous variables reported as means and standard deviations. We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; p = 0.008). This effect waned at the 6-month follow-up. Secondary outcome measures for burnout (subscales of the MBI-HSS-MP), demoralization (DS II), and connectedness (WCS) favored the MBSR + PAP arm; however, these effects did not survive correction for multiple comparisons. A mixed RM-ANCOVA was conducted to control for baseline differences in outcome measures. Sensitivity analyses were conducted, adjusting for baseline differences in gender and clustering within group cohorts. Study limitations that affect the generalizability of results include a small sample size, homogenous study population, and significant differences in intervention intensity.

Conclusions

This trial met its primary endpoint: group psilocybin-assisted therapy plus MBSR was associated with clinically significant improvement in depressive symptoms without serious AEs and with greater reduction in symptoms than MBSR alone. Our findings suggest that integrating psilocybin with mindfulness training may represent a promising treatment for depression and burnout among physicians and nurses. Larger trials are needed to establish efficacy, generalizability, and durability of these effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MindfulnessCOVID-19PsilocybinBurnout, ProfessionalHealth PersonnelDepressionPsychotherapy, GroupHumansFemaleMaleAdultMiddle AgedSARS-CoV-2Treatment Outcome

Substanzen

Psilocybin

Autor:innen und Institutionen

  • Huntsman Mental Health Institute, University of Utah, Salt Lake City, Utah, United States of America.
  • Department of Internal Medicine, Section of Palliative Medicine, University of Utah, Salt Lake City, Utah, United States of America.
  • Geriatrics Extended Care, George E Whalen Veterans Affairs Hospital, Salt Lake City, Utah, United States of America.
  • Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States of America.
  • Sanford Institute for Empathy and Compassion, University of California San Diego, San Diego, California, United States of America.
  • Department of Psychiatry, University of California San Diego, San Diego, California, United States of America.

ORCID-Profile: Benjamin R Lewis, Kevin Byrne, Madeleine Odette

Förderung

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NIDA NIH HHS
  • Heffter Research Institute
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Intramural Research Program, National Institute on Drug Abuse

Zitieren

APA

Lewis, B. R., Hendrick, J., Byrne, K., Odette, M., Wu, C., & Garland, E. L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22(9), e1004519. https://doi.org/10.1371/journal.pmed.1004519

Vancouver

Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine. 2025;22(9):e1004519. doi:10.1371/journal.pmed.1004519

BibTeX
@article{Lewis2025,
  author = {Lewis, Benjamin R and Hendrick, John and Byrne, Kevin and Odette, Madeleine and Wu, Chaorong and Garland, Eric L},
  title = {Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial},
  journal = {PLOS Medicine},
  year = {2025},
  volume = {22},
  number = {9},
  pages = {e1004519},
  doi = {10.1371/journal.pmed.1004519}
}
Kostenlos starten →